Who We Are
Hypha’s aim is to deliver a first-class service to our clients. We are proud of our high standards and reputation in the industry, derived from our ethos for delivering top quality science in our areas of expertise.
We have a global reach and have worked with over a hundred companies worldwide to solve critical problems. We work collaboratively with clients to provide custom solutions that meet their needs.
Hypha was founded in 2004 by CEO Liam Evans and CSO Jonathan Steele, originally as a natural products drug discovery company focussing on novel compounds produced by Hypha’s collection of microbes.
Hypha quickly developed complementary technology in microbial biotransformation and purification expertise, building on existing skills in complex natural products chemistry. Since then, Hypha has expanded its technology base to become the go-to company for metabolite synthesis, complex purification and structural characterisation for pharma and agrochemical companies worldwide.
Delivering a first class service to our clients worldwide
We look forward to engaging Hypha in the future because their team is professional, and their services complement our internal synthetic efforts for delivering new molecules.
Q2 2023 Newsletter – acyl glucuronides, hydroxylated metabolites and latest blogs
Purification Chemist Job
Molecules that Matter – Rezafungin
Meet us at one of the conferences we’ll be attending this year
Read about our publications in the fields of metabolite synthesis, biotransformation and natural products chemistry
Access brochures on drug metabolite synthesis, Hypha’s one-stop metabolite shop and the PolyCYPs platform
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.